Company: SHPH
Filing Date: 2025-11-21
Form Type: 8-K
Source: 0001493152-25-024618
Chunk: 0

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-11-21
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item
1.01. Entry into a Material Definitive Agreement.

As
previously disclosed by the Company in its Current Report on Form 8-K, filed with the U. S. Securities and Exchange Commission (the “ SEC”)
on October 21, 2025, on October 15, 2025, Shuttle Pharmaceuticals Holdings, Inc. (the “ Company”) received a letter from Theradex
Systems, Inc. (“ Theradex”), providing written notice of termination of the master agreement, dated November 1, 2018 (the
“ Master Agreement”), between Shuttle Pharmaceuticals, Inc. (the Company’s wholly-owned subsidiary) and Theradex, and
all work orders thereunder.

Pursuant
to the notice of termination, on November 20, 2025, the Company and Theradex entered into a release and settlement agreement (the
“ Settlement Agreement”), pursuant to which the Company will pay a partial payment of $300,000 to Theradex
as full and final payment of any and all claims relating to the debt or obligation previously owed by the Company to Theradex,
totalling approximately $557,000 (the “ Outstanding Liabilities”) and in consideration of such payment, each party will
release, acquit and discharge each other from all claims arising from the Outstanding Liabilities and Theradex will properly wind
down the Clinical Trials (as defined below) in a manner compliant with the Food and Drug Administration. After the payments pursuant
to the Settlement Agreement, the Company will still owe amounts, under five separate research site agreements between the Company
and various hospitals, as disclosed in the Settlement Agreement. The Company currently estimates these amounts to be approximately
$750,000.